- Details
- Oliver Sartor joins Phillip Koo to discuss the United State FDA approval of Pluvicto™ (177Lu-PSMA-617) as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer (mCRPC). They discuss currently enrolling in clinical trials with Pluvicto in the pre-chemotherapy treated mCRPC patient population. They look further into the future discu...
|
- Details
- Drs Charles Ryan and Alicia Morgans discuss the approval of Pluvicto TM (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617). Pluvicto was approved based on the pivotal Phase III VISION trial which evaluated men who had post androgen receptor pathway inhibitor therapy and post docetaxel or docetaxel and cabazitaxel chemotherapy, who were randomized to a protocol-defined...
|
- Details
- Alicia Morgans and Oliver Sartor discuss additional data from the VISION trial that was recently presented at ESMO 2021. Dr. Sartor discusses the health-related quality of life findings from the VISON specifically pain and symptomatic skeletal events. Dr. Sartor offers the background on the VISION trial, while also describing the patient cohorts. Dr. Sartor discusses how the trial patients randomi...
|
- Details
- Alicia Morgans and Karim Fizazi discuss the VISION trial, evaluating new patient-reported data. This patient-reported health-related quality of life data was presented at ESMO 2021. They discuss the VISION trial design, primary trial endpoints, and the importance of preserving good patient quality of life during advanced prostate cancer treatment. Biographies: Karim Fizazi, MD, Ph.D., is a medical...
|
- Details
- Alicia Morgans, MD, MPH, is joined by Michael Morris, MD, to discuss the phase III VISION trial results and the practice-changing implications when lutetium-177-PSMA-617 is FDA approved. The VISION trial evaluated men who had post androgen receptor pathway inhibitor therapy and post docetaxel or docetaxel and cabazitaxel chemotherapy, who were randomized to a protocol-defined standard of care with...
|
- Details
- Oliver Sartor, MD, joins Charles Ryan, MD in a conversation about the New England Journal of Medicine publication "Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer" known as the VISION trial. The VISION Trial is an international, open-label, phase 3 trial evaluating 177Lu-PSMA-617 in patients who had metastatic castration-resistant prostate cancer previously treated with a...
|
- Details
- Oliver Sartor, MD, the CO-PI on the VISION Trial joins Alicia Morgans, MD, MPH in a conversation on the practice-changing VISION Trial results presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. 177Lu-PSMA-617 is a targeted radioligand therapy that delivers ß-particle radiation to PSMA-expressing cells and the surrounding microenvironment. The VISION study was an int...
|
- Details
- Men who received 177Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death (median OS benefit of 4 months) and a 60% reduction in the risk of radiographic disease progression or death (median rPFS benefit of 5 months) compared to best standard of care alone. Mary-Ellen Taplin, Professor of Medicine and a GU Medical Oncologist at Dana-Farber Cancer Institute, joins Alicia Morga...
|
- Details
- In a plenary presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Michael Morris, MD, presented awaited results of the Phase III VISION trial. The study is evaluating the efficacy and safety of 177Lu-PSMA-617, a targeted radioligand therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to best standard o...
|
- Details
- Recorded Date: September 8, 2020 The coronavirus disease 2019 (COVID-19) (SARS-CoV-2) pandemic necessitated rapid changes in medical practice. Many of these changes may add value to care, creating opportunities going forward. In this journal club, Zachary Klaassen, MD, MSc, and Christorpher Wallis, MD, PhD, discuss the impacts of the COVID-19 pandemic on genitourinary cancer care, and how we can r...
|
